Core Viewpoint - Sartorius achieved a sales revenue of €3.538 billion in the fiscal year 2025, representing a year-on-year growth of 7.6% [2][3] Group Business Development - The sales revenue growth was driven by the Bioprocess Solutions segment, which generated €2.865 billion, up 9.5% year-on-year, primarily due to strong demand for high-margin consumables like filters and single-use bags [2][3][7] - The Laboratory Products and Services segment reported sales of €673 million, with a modest growth of 0.2% year-on-year [2][10] - The overall sales growth was supported by a basic EBITDA increase of 11.2%, reaching €1.052 billion, with a profit margin improvement from 28.0% to 29.7% [4] Regional Performance - All regions contributed to sales growth: EMEA region grew by 5.8% to €1.467 billion, the Americas increased by 8.9% to €1.251 billion, and the Asia-Pacific region also saw an 8.9% rise, reaching €820 million [4] Financial Performance - Basic net profit rose by 18.2% to €331 million, with basic earnings per share increasing to €4.78 from €4.05 [5] - The company’s employee count increased to 14,042, reflecting a growth of 514 employees compared to the end of 2024 [5] - The net asset ratio improved to 39.8% from 38.6% in 2024, and the net debt to basic EBITDA ratio decreased to 3.55 from 3.96 [5] Long-term Investment and Infrastructure - Sartorius continued to invest in long-term growth, with total capital expenditure reaching €442 million, representing 12.5% of sales revenue [6] - Key expansions included the bioprocess technology production facility in France and the membrane and filter production line in Germany [6] Bioprocess Solutions Segment - This segment accounted for over 75% of total sales, achieving a significant growth of 9.5% to €2.865 billion, driven by strong demand for consumables [7][8] - Basic EBITDA for this segment increased by 15.2% to €907 million, with a profit margin rise to 31.7% [7] Laboratory Products and Services Segment - This segment showed resilience in a challenging market, with sales reaching €673 million, recovering to last year's levels by December [10] - The segment's basic EBITDA decreased by 8.6% to €145 million, with a profit margin of 21.5% [10][11] 2026 Performance Guidance - For fiscal year 2026, Sartorius expects continued profitable growth, with sales revenue projected to increase by approximately 5% to 9% [12][14] - The Bioprocess Solutions segment is anticipated to grow by 6% to 10%, while the Laboratory Products and Services segment is expected to grow by 2% to 6% [14]